Identification

Name
Danaparoid
Accession Number
DB06754
Type
Small Molecule
Groups
Approved, Withdrawn
Description

Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans [2]. The active constituents are heparan, dermatan and Chondroitin sulfate [4], and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity that works by inhibiting activated factor X (Factor Xa) and activated factor II (Factor IIa). It is chemically distinct from heparin by containing different protein binding properties, thus has lower cross-reactivity in heparin-intolerant patients. Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication and prevention of post-operative deep venous thrombosis (DVT). While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer. The use of Orgaran™ was discontinued in the United States however it is available in several other countries including European countries and Japan. Danaparoid sodium is the common salt form in therapeutic preparations and is typically administered subcutaneously.

Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Danaparoid sodium5004UU3156Not AvailableNot applicable
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OrgaranSolution750 unitIntravenous; SubcutaneousAspen Pharmacare Canada Inc.1995-12-31Not applicableCanada
Categories
UNII
BI6GY4U9CW
CAS number
308068-55-5
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Indicated for the prophylaxis of post-operative deep venous thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients undergoing elective hip replacement surgery [FDA Label].

Structured Indications
Pharmacodynamics

Danaparoid contains a mixture of heparan sulfate, dermatan sulfate and chondroitin sulfate in amounts of approximately 84%, 12% and 4%, respectively [3]. Danaparoid is as an antithrombotic agent that prevents the formation of fibrin in the coagulation pathway. It has a high antifactor Xa to antifactor IIa (thrombin) activity that primarily works via antithrombin III-mediated inhibition of factor Xa [3]. The ratio of antifactor Xa to antifactor II activity is ≥ 20:1 [3]. Danaparoid has a minor effect on platelet function and aggregation [FDA Label]. In a worldwide compassionate-use programme involving a total of 667 patients with heparin-induced thrombocytopenia (HIT), treatment with danaparoid resulted in 93% of successful outcomes in resolving HIT [3].

In healthy volunteers, danaparoid caused significantly less prolongation o f the activated partial thromboplastin time (APTT) and was associated with a significantly lower thrombin time than unfractionated heparin (UFH) and low molecular weight heparins (LMWHs) [3]. Danaparoid displays lower lipolytic activity than UFH in vitro and in healthy individuals, leading to lower plasma levels of free fatty acids [3]. Danaparoid has been associated with the cross-reactivity with pathogenic heparin-induced platelet-factor 4 (PF4) antibodies, which occurs in about 10 % or more by in vitro testing [1]. The clinical relevance of this effect is not fully understood [1].

Mechanism of action

In the coagulation cascade leading to clot formation, factor X and factor II requires activation to promote subsequent conversion of fibrinogen to fibrin. The mechanism of action of danaparoid resulting in anticoagulant and antithrombic effects involves a complex interaction between 2 components, factor IIa and in particular, factor Xa [3]. Via binding to antithrombin and inducing a conformational change [A32579], danaparoid enhances and catalyzes the the binding of factor Xa to antithrombin, which induces antithrombin-mediated inactivation of factor Xa. This leads to inhibition of thrombin generation and subsequently, thrombus formation [2]. Danaparoid also weakly enhances antithrombin III and heparin cofactor II inactivation of factor IIa [2]. There is evidence that danaparoid also suppresses the activation of factor IX which, in conjunction with simultaneous inhibition of factor X, may lead to antithrombic effects [3].

TargetActionsOrganism
AAntithrombin-III
positive allosteric modulator
Human
Absorption

Pharmacokinetic studies on danaparoid are based on the kinetics of its anticoagulant activities, which are mostly antifactor Xa and antifactor IIa activities. The bioavailability of danaparoid is 100% following subcutaneous administration [FDA Label]. Following administration of single subcutaneous doses of 750, 1500, 2250, and 3250 anti-Xa units of danaparoid, the peak plasma anti-Xa activities were 102.4, 206.1, 283.9, and 403.4 mU/mL, respectively [FDA Label]. The time to reach maximum anti-Xa activity is approximately 2-5 hours [FDA Label].

Volume of distribution

Pharmacokinetic studies on danaparoid are based on the kinetics of its anticoagulant activities, which are mostly anti factor Xa and anti factor IIa activities. The volumes of distribution of anti-Xa and anti-IIa activities are 9.1 L and 7.3-9.0 L, respectively [3].

Protein binding
Not Available
Metabolism

There is no evidence of hepatic metabolism and danaparoid is unlikely to undergo cellular metabolism [3].

Route of elimination

Renal excretion is the main route of elimination, accounting for approximately 40-50% of the total clearance of antifactor Xa activity following intravenous administration of danaparoid [3]. Therefore in patients with severe renal impairment, the elimination half-life of anti-Xa activity may be prolonged [FDA Label].

Half life

Pharmacokinetic studies on danaparoid are based on the kinetics of its anticoagulant activities, which are mostly anti factor Xa and anti factor IIa activities. The elimination half-life ranges from 19.2 to 24.5 hours during anti-Xa activity and ranges from 1.8 to 4.3 hours during anti-IIa activity [3].

Clearance

Pharmacokinetic studies on danaparoid are based on the kinetics of its anticoagulant activities, which are mostly anti factor Xa and anti factor IIa activities. Total plasma clearance is about 0.36 L/h during anti-Xa activity, which may be accelerated with higher body surface area [FDA Label]. Total plasma clearance during anti-IIa activity ranges from 2.3 to 3 L [3].

Toxicity

Subcutaneous administration of a single dose at 3800 anti-Xa units/kg, which is 20.5 times the recommended dose for humans based on body surface area, was found to be lethal to female rats. Lethal effects were seen in male rats when administering a single subcutaneous dose at 15200 anti-Xa units/kg, which is approximately 82 times the recommended human dose based on body surface area [FDA Label]. In rats, the symptoms of acute toxicity following intravenous administration included respiratory depression, prostration and twitching [FDA Label].

Accidental overdosage of danaparoid may lead to severe bleeding complications. While protamine sulfate may partially neutralize the anti-Xa actions of danaparoid, there is no evidence that it is capable of reducing severe non-surgical bleeding during treatment of danaparoid. In case of serious bleeding, danaparoid should be discontinued and blood transfusions should be administered if necessary. Withdrawal of danaparoid is expected to restore the coagulation balance without rebound phenomenon [FDA Label].

There is no evidence of danaparoid to have a potential to induce carcinogenesis, mutagenesis and impairment of fertility [FDA Label].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the anticoagulant activities of Danaparoid.Investigational
AbciximabAbciximab may increase the anticoagulant activities of Danaparoid.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Danaparoid.Approved, Investigational
AcemetacinThe risk or severity of bleeding can be increased when Danaparoid is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Danaparoid.Approved, Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Danaparoid.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Danaparoid.Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
AllylestrenolThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Danaparoid.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Danaparoid.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Danaparoid.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Danaparoid.Approved
AltrenogestThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Altrenogest.Vet Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Danaparoid.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Danaparoid.Approved
AncrodAncrod may increase the anticoagulant activities of Danaparoid.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Danaparoid.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Danaparoid.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Danaparoid.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Danaparoid.Approved, Investigational
Antithrombin III humanDanaparoid may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Danaparoid.Approved
ApocyninApocynin may increase the anticoagulant activities of Danaparoid.Investigational
ApremilastApremilast may increase the anticoagulant activities of Danaparoid.Approved, Investigational
AprotininThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArdeparinArdeparin may increase the anticoagulant activities of Danaparoid.Approved, Investigational, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Danaparoid.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Danaparoid.Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Danaparoid.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Danaparoid.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Danaparoid is combined with Azficel-T.Approved, Investigational
BalsalazideBalsalazide may increase the anticoagulant activities of Danaparoid.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Danaparoid.Experimental
BecaplerminBecaplermin may increase the anticoagulant activities of Danaparoid.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Danaparoid.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Danaparoid.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Danaparoid.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Danaparoid.Withdrawn
BenzydamineBenzydamine may increase the anticoagulant activities of Danaparoid.Approved
BeraprostBeraprost may increase the anticoagulant activities of Danaparoid.Investigational
BevoniumBevonium may increase the anticoagulant activities of Danaparoid.Experimental
BivalirudinBivalirudin may increase the anticoagulant activities of Danaparoid.Approved, Investigational
BrinaseBrinase may increase the anticoagulant activities of Danaparoid.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Danaparoid.Approved
BucillamineBucillamine may increase the anticoagulant activities of Danaparoid.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Danaparoid.Approved, Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Danaparoid.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Danaparoid.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Danaparoid.Investigational
CangrelorCangrelor may increase the anticoagulant activities of Danaparoid.Approved
CaplacizumabCaplacizumab may increase the anticoagulant activities of Danaparoid.Investigational
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Danaparoid.Experimental, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Danaparoid.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Danaparoid.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Danaparoid.Approved, Investigational
CertoparinDanaparoid may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineChloroquine may increase the anticoagulant activities of Danaparoid.Approved, Investigational, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Danaparoid.Investigational, Withdrawn
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Danaparoid.Approved
CilostazolCilostazol may increase the anticoagulant activities of Danaparoid.Approved, Investigational
Citric AcidCitric Acid may increase the anticoagulant activities of Danaparoid.Approved, Nutraceutical, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Danaparoid.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Danaparoid.Approved
CloricromenCloricromen may increase the anticoagulant activities of Danaparoid.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Danaparoid.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Danaparoid is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensConjugated estrogens may decrease the anticoagulant activities of Danaparoid.Approved
CurcuminCurcumin may increase the anticoagulant activities of Danaparoid.Approved, Investigational
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Danaparoid.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Danaparoid.Experimental
DalteparinDanaparoid may increase the anticoagulant activities of Dalteparin.Approved
DarexabanDanaparoid may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Danaparoid.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Danaparoid is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Danaparoid.Approved, Investigational
DemegestoneThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Demegestone.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Danaparoid is combined with Deoxycholic Acid.Approved
DersalazineDersalazine may increase the anticoagulant activities of Danaparoid.Investigational
DesirudinDanaparoid may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Danaparoid.Investigational
DesogestrelThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Desogestrel.Approved
DextranDanaparoid may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DiclofenacDiclofenac may increase the anticoagulant activities of Danaparoid.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Danaparoid.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Danaparoid.Approved, Investigational
DienogestThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Danaparoid.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Danaparoid.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Danaparoid.Approved, Investigational
DiphenadioneDiphenadione may increase the anticoagulant activities of Danaparoid.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Danaparoid.Approved
DitazoleDitazole may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Danaparoid.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Danaparoid.Withdrawn
DuvelisibDuvelisib may increase the anticoagulant activities of Danaparoid.Investigational
DydrogesteroneThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
E-6201E-6201 may increase the anticoagulant activities of Danaparoid.Investigational
Edetic AcidEdetic Acid may increase the anticoagulant activities of Danaparoid.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Danaparoid.Approved
EnoxaparinEnoxaparin may increase the anticoagulant activities of Danaparoid.Approved
EpimestrolEpimestrol may decrease the anticoagulant activities of Danaparoid.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Danaparoid.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Danaparoid.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Danaparoid.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Danaparoid.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Danaparoid.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Danaparoid.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Danaparoid.Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Danaparoid.Approved, Investigational, Vet Approved
Estradiol acetateEstradiol acetate may decrease the anticoagulant activities of Danaparoid.Approved, Investigational, Vet Approved
Estradiol cypionateEstradiol cypionate may decrease the anticoagulant activities of Danaparoid.Approved, Investigational, Vet Approved
Estradiol valerateEstradiol valerate may decrease the anticoagulant activities of Danaparoid.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Danaparoid.Approved, Investigational, Vet Approved
Estrogens, esterifiedEstrogens, esterified may decrease the anticoagulant activities of Danaparoid.Approved
EstroneEstrone may decrease the anticoagulant activities of Danaparoid.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Danaparoid.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Danaparoid.Experimental
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Danaparoid.Approved
Ethyl biscoumacetateDanaparoid may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthynodiolThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Ethynodiol.Experimental
EtodolacEtodolac may increase the anticoagulant activities of Danaparoid.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Danaparoid.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Danaparoid.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Danaparoid.Approved, Investigational
ExisulindExisulind may increase the anticoagulant activities of Danaparoid.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Danaparoid.Experimental
FenbufenFenbufen may increase the anticoagulant activities of Danaparoid.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Danaparoid.Approved
FentiazacFentiazac may increase the anticoagulant activities of Danaparoid.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Danaparoid.Experimental
Ferulic acidFerulic acid may increase the anticoagulant activities of Danaparoid.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Danaparoid.Investigational
FloctafenineFloctafenine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
FluindioneDanaparoid may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunixinFlunixin may increase the anticoagulant activities of Danaparoid.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Danaparoid.Experimental
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Danaparoid.Approved, Investigational
FondaparinuxDanaparoid may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Danaparoid.Approved, Investigational
GabexateDanaparoid may increase the anticoagulant activities of Gabexate.Investigational
GenisteinGenistein may decrease the anticoagulant activities of Danaparoid.Investigational
GestodeneThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Gestrinone.Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Danaparoid.Experimental
HeminHemin may increase the anticoagulant activities of Danaparoid.Approved, Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Danaparoid.Experimental
HeparinHeparin may increase the anticoagulant activities of Danaparoid.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Danaparoid.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Danaparoid.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Danaparoid.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Danaparoid is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Danaparoid.Approved
IbudilastIbudilast may increase the anticoagulant activities of Danaparoid.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Danaparoid.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Danaparoid.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Danaparoid.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Danaparoid.Approved, Investigational, Nutraceutical
IdraparinuxIdraparinux may increase the anticoagulant activities of Danaparoid.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Danaparoid.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Danaparoid.Investigational
IloprostIloprost may increase the anticoagulant activities of Danaparoid.Approved, Investigational
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Danaparoid.Experimental
IndobufenIndobufen may increase the anticoagulant activities of Danaparoid.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Danaparoid.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Danaparoid.Withdrawn
IsoxicamIsoxicam may increase the anticoagulant activities of Danaparoid.Withdrawn
KebuzoneKebuzone may increase the anticoagulant activities of Danaparoid.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Danaparoid.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Danaparoid.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Danaparoid.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Danaparoid.Approved, Investigational
LepirudinLepirudin may increase the anticoagulant activities of Danaparoid.Approved
LetaxabanDanaparoid may increase the anticoagulant activities of Letaxaban.Investigational
LevonorgestrelThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Danaparoid.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Danaparoid.Experimental
LisofyllineLisofylline may increase the anticoagulant activities of Danaparoid.Investigational
LonazolacLonazolac may increase the anticoagulant activities of Danaparoid.Experimental
LornoxicamLornoxicam may increase the anticoagulant activities of Danaparoid.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Danaparoid.Approved, Investigational
LumiracoxibLumiracoxib may increase the anticoagulant activities of Danaparoid.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Danaparoid.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Danaparoid.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Danaparoid.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Danaparoid.Approved
Megestrol acetateThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MelagatranDanaparoid may increase the anticoagulant activities of Melagatran.Experimental
MeloxicamMeloxicam may increase the anticoagulant activities of Danaparoid.Approved, Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Danaparoid.Approved
MestranolMestranol may decrease the anticoagulant activities of Danaparoid.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Danaparoid.Approved, Investigational, Withdrawn
MethallenestrilMethallenestril may decrease the anticoagulant activities of Danaparoid.Experimental
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Danaparoid.Approved, Vet Approved
MethylestrenoloneThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Methylestrenolone.Experimental
MilrinoneMilrinone may increase the anticoagulant activities of Danaparoid.Approved
MizoribineMizoribine may increase the anticoagulant activities of Danaparoid.Investigational
MofebutazoneMofebutazone may increase the anticoagulant activities of Danaparoid.Experimental
MoxestrolMoxestrol may decrease the anticoagulant activities of Danaparoid.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Danaparoid.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Danaparoid.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Danaparoid.Approved
NadroparinDanaparoid may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatNafamostat may increase the anticoagulant activities of Danaparoid.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Danaparoid.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Danaparoid.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Danaparoid.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Danaparoid.Approved, Investigational
NifenazoneNifenazone may increase the anticoagulant activities of Danaparoid.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Danaparoid.Approved
NimesulideNimesulide may increase the anticoagulant activities of Danaparoid.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Danaparoid is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Danaparoid.Investigational
NomegestrolThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Norethisterone.Approved
NorgestrienoneThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Norgestrienone.Experimental
ObinutuzumabThe risk or severity of adverse effects can be increased when Danaparoid is combined with Obinutuzumab.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Danaparoid.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Danaparoid.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Danaparoid is combined with Omacetaxine mepesuccinate.Approved, Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Danaparoid.Approved, Nutraceutical
Omega-3-carboxylic acidsThe therapeutic efficacy of Danaparoid can be increased when used in combination with Omega-3-carboxylic acids.Approved, Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Danaparoid.Vet Approved
OtamixabanOtamixaban may increase the anticoagulant activities of Danaparoid.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Danaparoid.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Danaparoid.Investigational
ParecoxibParecoxib may increase the anticoagulant activities of Danaparoid.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Danaparoid.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Danaparoid.Approved, Investigational
Pentaerythritol TetranitratePentaerythritol Tetranitrate may increase the anticoagulant activities of Danaparoid.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Danaparoid.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Danaparoid.Approved, Investigational
PhenindionePhenindione may increase the anticoagulant activities of Danaparoid.Approved, Investigational
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Danaparoid.Approved, Investigational
Phenyl aminosalicylatePhenyl aminosalicylate may increase the anticoagulant activities of Danaparoid.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Danaparoid.Approved, Vet Approved
PicotamidePicotamide may increase the anticoagulant activities of Danaparoid.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Danaparoid.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Danaparoid.Approved, Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Danaparoid.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Danaparoid.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Danaparoid.Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Danaparoid.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Danaparoid.Approved
ProgesteroneThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Danaparoid.Experimental
PromegestoneThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Danaparoid.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Danaparoid.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Danaparoid.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Danaparoid.Experimental
Protein CDanaparoid may increase the anticoagulant activities of Protein C.Approved
Protein S humanDanaparoid may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeDanaparoid may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299PTC299 may increase the anticoagulant activities of Danaparoid.Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Danaparoid.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Danaparoid.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Danaparoid.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Danaparoid.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Danaparoid.Approved, Investigational
ReviparinDanaparoid may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Danaparoid.Approved
RivaroxabanDanaparoid may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Danaparoid.Approved, Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Danaparoid.Approved, Investigational
SalicylamideSalicylamide may increase the anticoagulant activities of Danaparoid.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Danaparoid.Approved, Investigational, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Danaparoid.Approved
SarpogrelateSarpogrelate may increase the anticoagulant activities of Danaparoid.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Danaparoid.Experimental
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Danaparoid.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Danaparoid.Approved
SemapimodSemapimod may increase the anticoagulant activities of Danaparoid.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Danaparoid.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Danaparoid.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Danaparoid.Approved, Vet Approved
SRT501SRT501 may increase the anticoagulant activities of Danaparoid.Investigational
StreptokinaseStreptokinase may increase the anticoagulant activities of Danaparoid.Approved, Investigational
SugammadexSugammadex may increase the anticoagulant activities of Danaparoid.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Danaparoid.Approved
SulindacSulindac may increase the anticoagulant activities of Danaparoid.Approved, Investigational
SulodexideSulodexide may increase the anticoagulant activities of Danaparoid.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Danaparoid.Experimental
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Danaparoid.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Danaparoid.Approved
TarenflurbilTarenflurbil may increase the anticoagulant activities of Danaparoid.Investigational
TenecteplaseTenecteplase may increase the anticoagulant activities of Danaparoid.Approved
TenidapTenidap may increase the anticoagulant activities of Danaparoid.Experimental
TenoxicamTenoxicam may increase the anticoagulant activities of Danaparoid.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Danaparoid.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Danaparoid.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Danaparoid.Investigational
Testosterone cypionateThe therapeutic efficacy of Danaparoid can be increased when used in combination with Testosterone cypionate.Approved
Testosterone enanthateThe therapeutic efficacy of Danaparoid can be increased when used in combination with Testosterone enanthate.Approved
Testosterone undecanoateThe therapeutic efficacy of Danaparoid can be increased when used in combination with Testosterone undecanoate.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Danaparoid.Approved
TiboloneTibolone may increase the anticoagulant activities of Danaparoid.Approved, Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Danaparoid.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Danaparoid.Approved
TinoridineTinoridine may increase the anticoagulant activities of Danaparoid.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Danaparoid.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Danaparoid.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Danaparoid.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Danaparoid.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Danaparoid.Approved, Investigational
TolmetinTolmetin may increase the anticoagulant activities of Danaparoid.Approved
TositumomabThe risk or severity of adverse effects can be increased when Danaparoid is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Danaparoid.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Danaparoid.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Danaparoid.Approved, Investigational
TribenosideTribenoside may increase the anticoagulant activities of Danaparoid.Experimental
TriflusalTriflusal may increase the anticoagulant activities of Danaparoid.Approved, Investigational
TriptolideTriptolide may increase the anticoagulant activities of Danaparoid.Investigational
Trolamine salicylateTrolamine salicylate may increase the anticoagulant activities of Danaparoid.Approved
TroxerutinDanaparoid may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseUrokinase may increase the anticoagulant activities of Danaparoid.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Danaparoid.Approved, Investigational, Withdrawn
Vitamin EVitamin E may increase the anticoagulant activities of Danaparoid.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Danaparoid.Approved
WarfarinWarfarin may increase the anticoagulant activities of Danaparoid.Approved
XimelagatranXimelagatran may increase the anticoagulant activities of Danaparoid.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Danaparoid.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Danaparoid.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Danaparoid.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Danaparoid.Withdrawn
Food Interactions
Not Available

References

General References
  1. Kodityal S, Manhas AH, Udden M, Rice L: Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures. Eur J Haematol. 2003 Aug;71(2):109-13. [PubMed:12890149]
  2. Ibbotson T, Perry CM: Danaparoid: a review of its use in thromboembolic and coagulation disorders. Drugs. 2002;62(15):2283-314. [PubMed:12381232]
  3. Wilde MI, Markham A: Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs. 1997 Dec;54(6):903-24. [PubMed:9421696]
  4. 24. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 299-300). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
External Links
PubChem Substance
347910366
Wikipedia
Danaparoid
ATC Codes
B01AB09 — Danaparoid
AHFS Codes
  • 20:12.04.16 — Heparins
FDA label
Download (566 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedNot AvailableAcute HIT II (Heparin-induced Thrombocytopenia Type II)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionIntravenous; Subcutaneous750 unit
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Positive allosteric modulator
General Function
Serine-type endopeptidase inhibitor activity
Specific Function
Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory a...
Gene Name
SERPINC1
Uniprot ID
P01008
Uniprot Name
Antithrombin-III
Molecular Weight
52601.935 Da
References
  1. Liu J, Pedersen LC: Anticoagulant heparan sulfate: structural specificity and biosynthesis. Appl Microbiol Biotechnol. 2007 Feb;74(2):263-72. doi: 10.1007/s00253-006-0722-x. Epub 2006 Nov 28. [PubMed:17131147]

Drug created on September 14, 2010 10:20 / Updated on May 21, 2018 17:37